Rationing of drugs for rare diseases

PharmacoEconomics

Volumn 24, Issue 4, 2006, Pages 315-316

  Hughes, Dyfrig ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; ORPHAN DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HEALTH CARE PLANNING; HUMAN; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; RISK MANAGEMENT;

COST-BENEFIT ANALYSIS; HEALTH CARE RATIONING; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; PATIENT RIGHTS; RARE DISEASES; RISK SHARING, FINANCIAL;

EID: 33645824158     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624040-00001     Document Type: Editorial

References (7)

1. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? Q J Med 2005; 98: 829-36
2. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ 2005; 331: 1016-9
3. McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003; 56: 2407-19
4. Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics 2005; 31: 164-8
5. Chapman S, Reeve E, Rajaratnam G, et al. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ 2003; 326: 707-9
6. Møldrup C. No cure, no pay. BMJ 2005; 330: 1262-4
7. Sudlow CL, Counsell CE. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003; 326: 388-92